Is this you? Create Your Porfile
Avatar

Helge Bischoff

Heidelberg University

Publication

Featured researches published by Helge Bischoff.

Journal of Thoracic Oncology | 2017

MA07.05 EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements - Preliminary Results

Sebastian Michels; Masyar Gardizi; Petra Schmalz; Meike Thurat; Eva Pereira; Martin Sebastian; Enric Carcereny; Jesus Corral; Luis Paz-Ares; Enriqueta Felip; Christian Grohé; Delvys Rodriguez Abreu; Amelia Insa Molla; Helge Bischoff; Martin Reck; Niki Karachaliou; Andreas H. Scheel; Vanessa Brandes; Fischer Rieke; Lucia Nogova; Matthias Scheffler; Jeremy Franklin; Martin Hellmich; Bartomeu Massuti; Reinhard Buettner; Rafael Rosell; Jürgen Wolf

Value in Health | 2010

PCN20 MAINTENANCE ERLOTINIB VERSUS PEMETREXED FOR THE TREATMENT OF NON-SMALL CELL LUNG CANCER: INDIRECT COMPARISON APPLYING REAL-LIFE OUTCOMES

R Casciano; Helge Bischoff; M Nuijten; E Malangone; J Ray

Ejc Supplements | 2009

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)

Stefan Walzer; J. de Castro Carpeño; Alain Vergnenegre; Christos Chouaid; David Heigener; Helge Bischoff; M.C. Nicolson; Rick Aultman; Uwe Siebert

Journal of Clinical Oncology | 2007

IMRT and cetuximab in stage 3 non-small cell lung cancer: The NEAR trial (NCT00115518)

A. D. Jensen; M. W. Munter; Helge Bischoff; E. Herpel; R. Haselmann; Carmen Timke; Uwe Haberkorn; Peter E. Huber; Mike Thomas; Jürgen Debus; Klaus Herfarth

Journal of Clinical Oncology | 2018

A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER.

Jonathan W. Goldman; Julien Mazieres; Fabrice Barlesi; Marianna Koczywas; Konstantin H. Dragnev; Tuncay Goksel; Alexis B. Cortot; Nicolas Girard; Claas Wesseler; Helge Bischoff; Ernest Nadal; Keunchil Park; Shun Lu; Álvaro Taus; Manuel Cobo; Karla Hurt; Alan Chiang; Anwar Hossain; William J. John; Luis Paz-Ares

Value in Health | 2011

PCN94 HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS IN A REAL LIFE SETTING: BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB BASED THERAPY IN A EUROPEAN PILOT STUDY

Christos Chouaid; Helge Bischoff; Alain Vergnenegre; David Heigener; G. Taylor-Stokes; A. Roughley; Stefan Walzer

Value in Health | 2011

PCN8 REAL LIFE OUTCOMES IN 1ST LINE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC): A PILOT STUDY IN FRANCE AND GERMANY ANALYSING BEVACIZUMAB-BASED VERSUS NON-BEVACIZUMAB-BASED TREATMENTS

Helge Bischoff; Christos Chouaid; Alain Vergnenegre; David Heigener; G. Taylor-Stokes; A. Roughley; Stefan Walzer

Journal of Clinical Oncology | 2018

Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo) + pemetrexed (pem) + platinum (plt) for metastatic NSCLC.

Marina Chiara Garassino; Delvys Rodriguez-Abreu; Shirish M. Gadgeel; Emilio Esteban González; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Maximilian Hochmair; Steven Francis Powell; Susanna Y. Cheng; Helge Bischoff; N. Peled; Martin Reck; Rina Hui; Edward B. Garon; Michael Boyer; Jing Yang; Thomas A. Burke; Maria Catherine Pietanza; Leena Gandhi

Journal of Cancer Research and Clinical Oncology | 2018

Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer

Jan Stratmann; Sebastian Michels; Sofia Hornetz; Daniel C. Christoph; Sandra Sackmann; Werner Spengler; Helge Bischoff; Monica Schäfer; Jürgen Alt; Annette Müller; Eckart Laack; Martin Kimmich; Frank Griesinger; Martin Sebastian

Cancer Research | 2018

Abstract CT075: KEYNOTE-189: Randomized, double-blind, phase 3 study of pembrolizumab (pembro) or placebo plus pemetrexed (pem) and platinum as first-line therapy for metastatic NSCLC

Leena Gandhi; Delvys Rodgríguez-Abreu; Shirish M. Gadgeel; Emilio Esteban; Enriqueta Felip; Flávia De Angelis; Manuel Domine; Philip Clingan; Maximilian J. Hochmair; Steven M. Powell; Susanna Yee-Shan Cheng; Helge Bischoff; Nir Peled; Francesco Grossi; Ross Jennens; Martin Reck; Rina Hui; Edward B. Garon; Michael Boyer; Belen Rubio-Viqueira; Silvia Novello; Takayasu Kurata; Jhanelle E. Gray; John Vida; Ziwen Wei; Jing Yang; Harry Raftopoulos; M. Catherine Pietanza; Marina Chiara Garassino

Researchain Logo
Decentralizing Knowledge